Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 14
---
cular injection vs. intradermal MNA delivery of HelixNano's vaccine candidate HN-0001, through the proposed joint venture.

On August 21, the Company announced that the FDA accepted the Company's Type C Meeting request to formally discuss the D-MNA product development and gain further alignment on the clinical pathway. The Company has submitted its queries in writing and expects to receive a response from the FDA before the end of the third quarter of 2025.

On September 8, 2025, the Company announced that its SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin, has commenced patient recruitment in Cleveland clinic Abu Dhabi.

On September 12, 2025, the Company announced that James Quinlan, Chief Financial Officer of the Company, will be taking a medical leave of absence from the Company commencing on such date and that Carolyn Bonner was appointed as acting Chief Financial Officer of the Company in addition to maintaining her current role as President of the Company.

On September 17, 2025, the Company entered into a securities purchase agreement (the "Purchase Agreement") with Yorkville (as defined herein) in connection with the issuance and sale by the Company of a debenture (the "Debenture") in the principal amount of $8.0 million. The Company used a portion of the proceeds from the issuance of the Debenture to fully satisfy and discharge the approximately $1.7 million remaining outstanding balance of the $5.0 million aggregate principal amount of debentures that Yorkville purchased from the Company in May and June 2025 pursuant to a purchase agreement dated May 2, 2025. The Debenture is guaranteed by each of the Company's subsidiaries pursuant to a global guaranty agreement (the "Guaranty"). Interest will accrue on the outstanding principal amount of the Debenture at an annual rate of 8.00%, subject to a potential increase to 18.00% per annum upon the occurrence of certain events of default. The Debenture will mature on September 17, 2026. The foregoing descriptions of the Purchase Agreement, Guaranty and Debenture do not purport to be complete and are qualified in their entirety by reference to the full text of such documents, which are filed as exhibits hereto and are incorporated herein by reference.

Implications of Being an Emerging Growth Company

As a company with less than $1.235 billion in